Adaptimmune Therapeutics Plc (ADAP) Return on Investment ROI from the second quarter of 2025 to second quarter of 2024 and for the year 2025, average high and low, overall ranking from Jun 30 2025 to Jun 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)


Adaptimmune Therapeutics Plc's ROI from its second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Adaptimmune Therapeutics Plc's ROI in the second quarter of 2025?
Adaptimmune Therapeutics Plc recorded a cumulative net loss of $-170 million during 12 months ending in the second quarter of 2025, resulting in a negative return on investment (ROI) of -106.6%.

Within the Healthcare sector 733 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2025 from 3322 to 4261.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter
Y / Y Investment Change TTM -37.68 % -24.69 % -19.29 % 6.37 % -1.04 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 85 107 191 254 240
Return On Investment (TTM) -106.6 % -35.32 % -32.33 % -16.91 % -28.37 %
ADAP's Overall Ranking # 4261 # 3322 # 3325 # 2763 # 2525
Seq. Investment Change TTM -19.53 % -9.66 % -16.79 % 3.01 % -2.75 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -170 -70 -71 -45 -73

ADAP Company Profile >> Back to ADAP Roi Comparisons >> See Annual ADAP Return On Investment



Return On Investment ADAP's Ranking
Within: No.
Industry # 119
Sector # 734
Overall # 4261

Return On Investment Statistics
High Average Low
-16.91 %
-45.33 %
-106.6 %
(Sep 30 2024)   (Jun 30 2025)







Financial Statements
Adaptimmune Therapeutics Plc's II. Quarter Investments $ 85 Millions ADAP's Balance sheet
Adaptimmune Therapeutics Plc's II. Quarter Income $ -30 Millions Quarterly ADAP's Income Statement
ADAP's Income by Division See ADAP's Income by Division


ADAP Annual Return On Investment (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020
Total Investments in Millions 191 368 272 410 415
Y / Y Investment Growth -48.07 % 35.2 % -33.65 % -1.23 % 175.04 %
Net Income in Millions -71 -114 -165 -158 -130
Y / Y Net Income Growth - - - - -
Annual Return On Investment -37.08 % -30.97 % -60.84 % -38.57 % -31.35 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ADAP's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ADAP's Competitors
Subscribers only: Roi for Adaptimmune Therapeutics Plc's Suppliers
Subscribers only: Return On Investment for ADAP's Customers

Other Ratios
ADAP's Roa ADAP's Inventory Turnover Ratio ADAP's Growth Rates ADAP's Dividend Statistics
ADAP's Profitability Ratios ADAP's Asset Turnover Ratio ADAP's Dividend Growth
ADAP's Roe ADAP's Valuation Ratios ADAP's Financial Strength Ratios ADAP's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2025, within Healthcare Sector ROI

Date modified: 2026-09-26T07:28:25+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.